Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01744496 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain
A Phase 4 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 68
- Enrollment target
NCT01744496 is a Phase 4 study that has completed, run by UCB Biosciences. The registered enrollment target is 68 participants.
The verdict
NCT01744496, a Phase 4 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 68 participants
- Enrollment target
Study Summary
This trial is being conducted to compare the impact of Rotigotine and Placebo on Chronic Pain associated with Parkinson's Disease among patients with advanced stages of the disease.
Interventions
- DRUG Placebo
- DRUG Rotigotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01744496
The ClinicalTrials.gov registry entry for NCT01744496 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01744496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01744496 about?
NCT01744496 is a clinical study titled "Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain". This trial is being conducted to compare the impact of Rotigotine and Placebo on Chronic Pain associated with Parkinson's Disease among patients with advanced stages of the disease.
What is the current status of trial NCT01744496?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 68 participants. The study started on 2012-11. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01744496?
The interventions under investigation include: Placebo (DRUG), Rotigotine (DRUG).
Who is sponsoring clinical trial NCT01744496?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.